China Pharma Holdings (CPHI) Debt to Equity (2010 - 2026)

China Pharma Holdings has reported Debt to Equity for 17 years, with the latest figure at $0.05 in Q1 2026.

• For the quarter ending Q1 2026, Debt to Equity fell 85.74% year-over-year to $0.05; the trailing twelve-month figure through Mar 2026 stood at $0.05 (down 85.74% YoY), and the FY2025 full-year result was $0.09, down 72.01% from the prior year.
• Debt to Equity for Q1 2026 stood at $0.05, down from $0.09 in the prior quarter.
• The five-year high for Debt to Equity was $1.62 in Q3 2022, with the low at $0.05 in Q1 2026.
• Historically, Debt to Equity has averaged $0.48 across 5 years, with a median of $0.38 in 2024.
• Annual changes were most pronounced in 2022 — Debt to Equity jumped 116.53% — and 2026, when it tumbled 85.74%.
• China Pharma Holdings' Debt to Equity stood at $0.57 in 2022, then tumbled by 39.98% to $0.34 in 2023, then declined by 9.04% to $0.31 in 2024, then tumbled by 72.01% to $0.09 in 2025, then tumbled by 40.09% to $0.05 in 2026.
• The last three Debt to Equity figures came in at $0.05 (Q1 2026), $0.09 (Q4 2025), and $0.17 (Q3 2025), per Business Quant data.